Insulin pens market in India to reach US$ 400m

New insulin products will also boost the market.

The insulin pens market in India is seen to reach around US$ 400m in 2025 due to the rising prevalence of diabetes and introduction of new products for insulin delivery, information services firm, GlobalData, said.

In its report, GlobalData said firms such as Novo Nordisk, Eli Lilly, and Sanofi were the major players in India, covering 80% of the market in 2021.

It also reported that India posted the second largest number of adults diagnosed with diabetes worldwide, after China. This, after the country recorded an increasingly ageing population, urbanisation, and sedentary lifestyle leading to lack of physical activity, obesity, and weight gain.

Amidst the growing number of diabetes cases, pharmaceutical firm Roche’s, produced an innovation of insulin pens, called ACCU-FINE pen needles, which provides virtually painless insulin delivery.

Reacting to this, Shweta Yadav, medical devices analyst in GlobalData, pointed out that prioritising on product innovation will lead to timely insulin delivery, which will help address the management of diabetes.